ClinicalTrials.gg
RecruitingNCT07607925Updated Oct 30, 2026

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

A Phase 1/2 interventional study of GSK5926371 in Lymphoma, Non-Hodgkin, sponsored by GlaxoSmithKline. Recruiting at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 30, 2026Now RecruitingFirst sites in 5 new countries+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Lymphoma, Non-Hodgkin by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Lymphoma, Non-Hodgkin · GlaxoSmithKline.

Planned enrollment
11th of 31
49 · median 41
Started
2026
the only one that year
Phase 1/2
4 of 38
1 open now
Registered
38th of 38
by date

Among the 38 studies in Lymphoma, Non-Hodgkin by GlaxoSmithKline, this one is the 11th largest by planned enrollment of the 31 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 38th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 38 studies in Lymphoma, Non-Hodgkin by GlaxoSmithKline is open now, in 8 countries.

By country, each count listing its studies:

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Lymphoma, Non-Hodgkin by GlaxoSmithKline, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
  • GSK5926371
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed (R/R) B-NHL, for which systemic treatment is indicated,

    1. Has ,
    2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication;
    3. Has documented disease relapse, progression or disease refractory to the most recent , per Lugano criteria.:
  • Willing to use adequate (Participant of [POCBP] only).
  • Is capable of giving signed
  • Has an (ECOG) performance status of 0 to 2.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has a (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of disease.
  • Has had any major surgery within 4 weeks prior to the first dose of GSK5926371 or has not recovered from prior surgeries or complications.
  • Has a history of Progressive multifocal leukoencephalopathy (PML), current central nervous system (CNS) involvement by lymphoma, or a history of significant CNS disease such as uncontrolled seizures, stroke, epilepsy, CNS vasculitis, and neurodegenerative conditions.
  • Has an active uncontrolled infection.
  • Has received a prior stem cell transplant (allo-SCT) within 12 months prior to the first dose of GSK5926371 or has active requiring systemic therapy.
  • Has received a prior autologous stem cell transplant within 100 days prior to the first dose of GSK5926371.
  • Has received prior treatment with Chimeric antigen receptor T-cell (CAR-T) therapy within 12 weeks of first GSK5926371 administration.
  • Has received prior treatment with CD19- or CD20-targeting Bispecific antibody (BsAbs) within 8 weeks of the first dose of study intervention.
  • Has corrected (QTc) >450 milliseconds (msec) or QTc >480 msec for participants with bundle branch block.
  • Has significant cardiovascular disease such as uncontrolled arrhythmias, Class 3 or 4 congestive heart failure as defined by the Functional Classification, \<=45% by any methods in the 12 months of enrollment, unstable angina or acute coronary syndrome including myocardial infarction within 6 months of enrollment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    GSK5926371

    Drug: GSK5926371

Interventions

  • DrugGSK5926371

    GSK5926371 will be administered at different dose levels.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs)

    Time frame: Up to 28 days

  2. Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severity

    Time frame: Up to approximately 169 weeks

Secondary outcomes

  1. Number of participants with clinically meaningful changes in laboratory parameters, vital signs, and electrocardiogram (ECG)

    Time frame: Up to approximately 169 weeks

  2. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants in the ORR evaluable set with the best overall response of confirmed partial response (PR) or better per Lugano guidelines as assessed by investigator.

    Time frame: Up to approximately 169 weeks

  3. Maximum concentration (Cmax) of GSK5926371

    Time frame: Up to approximately 169 weeks

  4. Time to Cmax (Tmax) of GSK5926371

    Time frame: Up to approximately 169 weeks

  5. Area under the curve (AUC) of GSK5926371

    Time frame: Up to approximately 169 weeks

07

Study locations

22 of 22 sites recruiting
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10029, United States
    Recruiting
  • GSK Investigational Site
    Canton, Ohio 44718, United States
    Recruiting
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 1X6, Canada
    Recruiting
  • GSK Investigational Site
    Helsinki, 00290, Finland
    Recruiting
  • GSK Investigational Site
    Tampere, 33520, Finland
    Recruiting
  • GSK Investigational Site
    Pierre-Bénite, 69495, France
    Recruiting
  • GSK Investigational Site
    Rennes, 35033, France
    Recruiting
  • GSK Investigational Site
    Villejuif, 94805, France
    Recruiting
  • GSK Investigational Site
    Rozzano, MI 20089, Italy
    Recruiting
  • GSK Investigational Site
    Alessandria, 15121, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20133, Italy
    Recruiting
  • GSK Investigational Site
    Aichi, 460-0001, Japan
    Recruiting
  • GSK Investigational Site
    Chiba, 277-8577, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 135-8550, Japan
    Recruiting
  • GSK Investigational Site
    Barcelona, 08035, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 8036, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28040, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28041, Spain
    Recruiting
  • GSK Investigational Site
    Salamanca, Spain
    Recruiting
  • GSK Investigational Site
    Valencia, 46010, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2030, 42 months after the start.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's planned 42 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Sep 2029 → Jan 2030 and completion Sep 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
May 27, 2026
StartActual
Jun 19, 2026
Primary completionEst.
Jan 10, 2030was Sep 2029
CompletionEst.
Jan 10, 2030was Sep 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
19 sites added — first sites in Australia, Finland, France, Italy and Spain. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • GSK Investigational Site · Canton, United Statesno status→Recruiting
  • GSK Investigational Site · Toronto, Canadano status→Recruiting
  • GSK Investigational Site · Tokyo, Japanno status→Recruiting
Show 19 added (6 Spain, 3 France, 3 Italy, 2 United States, 2 Finland, 2 Japan, 1 Australia)
  • GSK Investigational Site · Iowa City, United States
  • GSK Investigational Site · New York, United States
  • GSK Investigational Site · Heidelberg, Australia
  • GSK Investigational Site · Helsinki, Finland
  • GSK Investigational Site · Tampere, Finland
  • GSK Investigational Site · Pierre-Bénite, France
  • GSK Investigational Site · Rennes, France
  • GSK Investigational Site · Villejuif, France
  • GSK Investigational Site · Rozzano, Italy
  • GSK Investigational Site · Alessandria, Italy
  • GSK Investigational Site · Milan, Italy
  • GSK Investigational Site · Aichi, Japan
  • GSK Investigational Site · Chiba, Japan
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Madrid, Spain
  • GSK Investigational Site · Madrid, Spain
  • GSK Investigational Site · Salamanca, Spain
  • GSK Investigational Site · Valencia, Spain
Oct 30, 2026
Start date
Jun 12, 2026→Jun 19, 2026 (actual)
Oct 30, 2026
Primary completion
Sep 24, 2029→Jan 10, 2030
Oct 30, 2026
Study completion
Sep 24, 2029→Jan 10, 2030
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    19 sites added — first sites in Australia, Finland, France, Italy and Spain. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • GSK Investigational Site · Canton, United Statesno status→Recruiting
    • GSK Investigational Site · Toronto, Canadano status→Recruiting
    • GSK Investigational Site · Tokyo, Japanno status→Recruiting
    Show 19 added (6 Spain, 3 France, 3 Italy, 2 United States, 2 Finland, 2 Japan, 1 Australia)
    • GSK Investigational Site · Iowa City, United States
    • GSK Investigational Site · New York, United States
    • GSK Investigational Site · Heidelberg, Australia
    • GSK Investigational Site · Helsinki, Finland
    • GSK Investigational Site · Tampere, Finland
    • GSK Investigational Site · Pierre-Bénite, France
    • GSK Investigational Site · Rennes, France
    • GSK Investigational Site · Villejuif, France
    • GSK Investigational Site · Rozzano, Italy
    • GSK Investigational Site · Alessandria, Italy
    • GSK Investigational Site · Milan, Italy
    • GSK Investigational Site · Aichi, Japan
    • GSK Investigational Site · Chiba, Japan
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Madrid, Spain
    • GSK Investigational Site · Madrid, Spain
    • GSK Investigational Site · Salamanca, Spain
    • GSK Investigational Site · Valencia, Spain
    Start date Jun 12, 2026→Jun 19, 2026 (now actual)
    Primary completion Sep 24, 2029→Jan 10, 2030
    Study completion Sep 24, 2029→Jan 10, 2030
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07607925
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jun 19, 2026
Primary completion
Jan 10, 2030 (estimated)
Completion
Jan 10, 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion